PRESS RELEASE

Mitsubishi Tanabe Pharma Corporation

Transfer of Tanabe Europe’s shares

Osaka, Japan, April 1, 2013—Mitsubishi Tanabe Pharma Corporation (President and Representative Director, CEO: Michihiro Tsuchiya) announced today that the Company entered into an agreement to transfer all shares of Tanabe Europe N.V., the Company’s consolidated subsidiary, to API Corporation (Headquarters: Tokyo; President Representative Director: Kiyoshi Kondo).

1. Grounds for a transfer
Mitsubishi Tanabe Pharma, guided by the “Medium-Term Management Plan 11-15—New Value Creation,” aims to focus management resources on our pharmaceutical operations by reorganizing operations. In this setting, the Company transferred its fine chemical operations in July, 2012. Subsequently, the Company decided to transfer the shares of Tanabe Europe, who is engaging in sales of chemicals and related products, in order to further focus management resources.
API Corporation, which is scheduled to acquire Tanabe Europe’s shares, is a consolidated subsidiary of Mitsubishi Chemical Corporation, one of the operating companies of the Mitsubishi Chemical Holdings Group. API is aggressively developing its business, centered on its healthcare and fine chemical operations, in accordance with its corporate philosophy: “API Corporation aims at developing into a ‘creative, R&D-oriented company’ in the field of specialty fine chemicals and contributing to a higher quality of life for people throughout the world.” The Company anticipates that the addition of Tanabe Europe’s sales operations of chemicals and related products will enable API Corporation to achieve impressive levels of growth in the future.
Mitsubishi Tanabe Pharma, through this transfer of shares, we aim to further focus management resources on our pharmaceutical operations and to develop into a “Company that Can Continue to Create New Value.”

2. Overview of Tanabe Europe N.V.
Location: Excelsiorlaan 83, 1930 Zaventem, Belgium
Representative: President and Director, Hiroshi Sato
Capital: €260,330
Net sales: €15,667,000 (estimation for fiscal year ended March 2013)
Operations: Sales of chemicals and related products
Number of employee: 6 (As of April 1, 2012)
3. Overview of API Corporation

Location: Nihonbashi Plaza Building, 9th Floor, 2-3-4, Nihonbashi, Chuo-ku, Tokyo, Japan
Representative: President and Representative Director, Kiyoshi Kondo
Capital: ¥4,000 million
Net sales: ¥27,327 million (fiscal year ended March, 2012)
Operations: Consigned manufacture of active pharmaceutical ingredients, intermediates and
investigational new drugs, consigned research and development, manufacture and marketing
of fine chemicals and reagents
Number of employee: 605 (As of April 1, 2012)
Major Shareholders: Mitsubishi Chemical Corporation (52.3%),
Mitsubishi Tanabe Pharma Corporation (47.7%)

4. Schedule of transfer of shares
Date of the contract: March 29, 2013
Date of transfer: June 1, 2013 (planned)

5. Impact of financial results
It is thought that the impact on Mitsubishi Tanabe Pharma's financial results will be minor.

<Media enquiry>
Corporate Communications Department
TEL: +81-6-6205-5211